Covid 19 Information

World Health Organization

Centers for Disease Control and Prevention

National Institute of Health

European Medicines Agency

COVID-19 data sources (Knowledge Portal on Innovation and Access to Medicines)

The Lancet

The New England Journal Of Medicine

Oxford Covid-19 Evidence service

The Royal College of Obstetricians and Gynaecologists (RCOG)

Italian Society of Pharmacology – English COVID-19 section

JAMA Network

International Union of Pharmacology and Clinical Pharmacology (IUPHAR)

NIPH-Live map of COVID-19 evidence

Springer Nature

The International Coalition of Medicines Regulatory Authorities (ICMRA)

Safety Monitoring Using WHO Global Database of Individual Case Safety Reports (ICSRs). Descriptive analysis of spontaneous report from VigiBase

Indian Council of Medical Research updated ethical guidance for biomedical and health research

African Vaccine Regulatory Forum (AVAREF) tools for Processing clinical trial applications by Ethics Committees and National Regulatory Authorities in Africa

Landscape of COVID-19 candidate vaccines/Draft

WHO Covid-19 vaccine safety manual

The Vaccine Centre & London School of Hygiene & Tropical Medicine

NZ Pharmacovigilance Centre Project encouraging feedback on COVID-19 Medication Safety Challenges in NZ

Johns Hopkins University-Coronavirus Resource Center

Official statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary.
SIF

Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary.
SIF

Simplified description of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Viral lifecycle and drug repurposing strategies.

Benefit-Risk evaluation for Remdesivir in COVID-19.
Drug Safety Research Unit

The challenging times and opportunities for pharmacovigilance in Africa during the COVID-19 pandemic.
African Chapter of ISoP / Executive Committee

ISoP infographic ‘Using Medicines Safely during the COVID-19 pandemic’. This infographic is aimed at patients and caregivers – feel free to display it in hospitals, clinics, pharmacies and any other public spaces appropriate to where medicines are obtained in your country.
ISoP

Posibles terapias para COVID-19: revision narrativa de seguridad I. Cloroquina / hidroxicloroquina y azitromicina.
Raquel Herrera Comoglio

Convalescent plasma in treatment of COVID-19 A review of evidence for a living systematic benefit-risk assessment.
Drug Safety Research Unit

Systematic benefit-risk assessment for the use of CQ or HCQ as a treatment for COVID-19.
Drug Safety Research Unit

Postmarketing studies can they provide a safety net for COVID-19 vaccines in the UK.
Drug Safety Research Unit

How To Investigate A Serious Adverse Event Reporting during Clinical Trial for a COVID-19 vaccine.
Drug Safety Research Unit

What is the difference between observed association and causal association, signals and evidence.
Drug Safety Research Unit

Lopinavir Ritonavir in the Treatment of COVID-19 A dynamic systemative benefit risk assessment.
Drug Safety Research Unit

DSRU Global Pharmacovigilance Observatory. Dissemination of evidence reviews about the safety of medicines and vaccines from around the world.
Drug Safety Research Unit

Challenges for drug repurposing in the COVID-19 pandemic era.
Drug Safety Research Unit

COVID vaccines – Questions & Answers from ISoP Israel Task Force.
ISoP Israel Chapter

ISoP infographic ‘COVID-19 Vaccine Safety’. This infographic is aimed at patients and caregivers – feel free to display it in hospitals, clinics, pharmacies and any other public spaces appropriate to where medicines are obtained in your country.
ISoP

Guide For the development of pharmacovigilance & Guideline On good pharmacovigilance practices in the context SARS-CoV-2 (COVID-19).
Colombian Pharmacovigilance Association (ACFV)